NCT06586320
Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment
Enrolling by Invitation
NAAges 18+InterventionalDiagnosticStardots AB
~40 participants
Updated 2025-02-20 on ClinicalTrials.gov
What's tested:150% of their routine home dopaminergic medications dose right in the clinicEvaluation of mathematical models
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Quantification of current IPD motor symptoms using kinetic tremor and Dyskinesia test
Measured over Day 1
Conditions
Where it's being run
1 sites across 1 statesNew Hampshire1
Study leadership
- Anas Hannoun, MD · PRINCIPAL_INVESTIGATOR · Dartmouth Hitchcock medical center, Manchester
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Quantification of current IPD motor symptoms using kinetic tremor and Dyskinesia testDay 1
ANLIVA® Hand Movement score of kinetic tremor test and dyskinesia test will be measured. Measurements are done on subjects upper limb movements. SD score of kinetic tremor test and dyskinesia test will be assessed by assessors. SD is acronym for Stardots-Dartmouth score. The SD score will be used to benchmark the ANLIVA® device assessments as a nonreference standard. Minimum value is 0; maximum value is 4. A higher value on the SD score means more movement disorder.